Due to lowered global demand, for the first time, Pfizer/BioNTech and Moderna are expected to see sales revenues for their COVID-19 vaccines take a major fall in Q2, but sales are expected to bounce back with jabs targeting new variants.
According to Airfinity’s recent forecast, revenue for Pfizer/BioNTech’s vaccine will drop by 63 percent from USD 13.2 billion in the first quarter of the year, to USD 4.8 billion in the second quarter. Airfinity also predicts Moderna to see sales fall by 62 percent to USD 2.3 billion in the second quarter from the previous quarter’s USD 5.9 billion.
“Demand for vaccines, particularly in high income countries, has been falling since the beginning of the year. We have seen countries canceling or postponing orders. Most notably the EU and UK pushing back deliveries to wait for new variant targeting vaccines to become available. The African Union and Covax also declined the option to buy more Moderna vaccines,” said Airfinity’s Analytics Director, Dr Matt Linley.
The forecast is based on data tracking the delivery of doses to countries around the world.
Hecho conVisme Infographic Maker
With the demand for new variant targeting vaccines that are expected to be used in autumn/winter vaccination campaigns, the analysis predicts that sales will bounce back for Pfizer/BioNTech and Moderna. The forecast expects Pfizer/BioNTech to generate USD 33 billion in sales this year from both its new and its original vaccine while Moderna’s sales are due to rebound to a total of USD 18.8 billion for 2022.
Hecho conVisme Infographic Maker
“New COVID-19 vaccines will boost sales for Pfizer/BioNTech and Moderna later in the year. The EU and UK have said these Omicron adapted vaccines will be rolled out this autumn pending regulatory approval. The U.S. has also signed a deal for 105 million doses of Pfizer’s updated jab. Once approved we expected these vaccines to be delivered swiftly,” Linley said.
